- Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabineIsabelle Trouilloud
Service d Oncologie Digestive, Hopital Europeen Georges Pompidou, AP HP, Universite Paris V, 20, rue Leblanc, 75015 Paris, France
Clin Res Hepatol Gastroenterol 35:364-74. 2011..After 10 years without significant progress in the treatment of pancreatic cancer patients, the hope that a significant improvement in the outcome of these patients can be achieved has been raised...
- Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)Isabelle Trouilloud
Hopital Europeen Georges Pompidou, Universite Paris Descartes, Paris, France
Eur J Cancer 50:3116-24. 2014..Whether a sequential approach alternating irinotecan, fluorouracil and gemcitabine may be effective and tolerable in patients with metastatic pancreatic cancer is unknown...
- FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM studyAziz Zaanan
Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, AP HP, 20 rue Leblanc, 75015 Paris, France
BMC Cancer 14:441. 2014..3 alternating with gemcitabine every two months. The present study assessed the efficacy and safety of FOLFOX after failure of the first-line therapy used in the FIRGEM study...
- Chemosensitivity in ovarian metastases from gastric cancer: a case seriesBertrand Brieau
Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, University of Paris Descartes, 20, rue Leblanc, 75015 Paris, France
Clin Res Hepatol Gastroenterol 37:289-95. 2013..To confirm these observations, a large retrospective study is ongoing...